Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling.

"Competing interests: The Technische Universität Dresden holds a patent for the use of Tfr2-ECD to treat heterotopic ossification and other related bone excess diseases (PCT/EP2018/065846). Moreover, a patent application has been filed at the European Patent Office for the use of Tfr2 blockade for the treatment of bone and hematological diseases (#18 177 441.5, 19.06.2018). MR, UB, UP, and LCH are the inventors of both patents. IT is a consultant for Kymab Ltd.: The other authors declare no competing interests."

"This work was supported by the German Research Foundation (DFG-SFB655 to LCH and UP; TRR-67 to VH and LCH; µBONE to MR and LCH; RA1923/12-1 to MR) and MedDrive start-up grants from the Medical Faculty of the Technische Universität Dresden (MR and UB). MR was supported by the Support-the-Best Initiative of the TUD funded through the Excellence initiative of the German Federal and State Governments. JHDB and GRW received a Wellcome Trust Joint Investigator Award (110141/Z/15/Z and 110140/Z/15/Z)."